Background: NKG2D recognises several ligands, including polymorphic major histocompatibility complex class I chain-related chain-related proteins A and B (MICA/B) and unique long 16-binding proteins (ULBPs). These ligands are present on cancer cells and are recognised by NKG2D in a cell-structure-sensing manner, triggering natural killer (NK) cell cytotoxicity. However, the mechanisms that control the expression of NKG2D ligands in malignant cells are poorly understood. 1-a,25-Dihydroxyvitamin D3 (1,25(OH)2D3) was recently shown to enhance the susceptibility of melanoma cells to the cytotoxicity of NK cells. However, the function of 1,25(OH)2D3 in other cancers and its potential mechanisms of action remain unknown.
As a first line of defence of the innate immune system, natural killer (NK) cells exert direct and indirect antitumour effects via their cytotoxic and immune-regulatory capacities. Their activity is controlled by signals derived from a variety of activating and inhibitory receptors that recognise ligands specifically expressed by malignant cells or stressed cells (Pegram et al, 2011; Fernandez-Messina et al, 2012; Mondelli, 2012; Saito et al, 2012) . NKG2D is one of the most important receptors mediating the cytotoxicity of NK cells against malignant cells (Ljunggren, 2008; Obeidy and Sharland, 2009; Tsuboi et al, 2011) . Ligands that bind NKG2D receptors include major histocompatibility complex (MHC) class I chain-related proteins A and B (MICA/B) and unique long 16-binding proteins 1 through 6 (ULBP1-6) (Nausch and Cerwenka, 2008; Brandt et al, 2009; Eisenring et al, 2010) . The expression of these ligands may be induced upon infection and other inducers of cellular stress and is unusual in normal cells (Champsaur and Lanier, 2010) . By binding to the NKG2D receptors on NK and T cells, NKG2D ligands may initiate an immune response against cells expressing these ligands. In mouse models, transfection with NKG2D ligands results in NKG2D-mediated tumour rejection (Cerwenka et al, 2001; Diefenbach et al, 2001) . Downregulation or complete knockout of NKG2D in mice results in an impaired immune response against tumour cells, higher expression levels of NKG2D ligands, and an increased incidence of certain tumours (Guerra et al, 2008; Wiemann et al, 2005) . One of the most important strategies by which tumour cells adapt to elude the immune response is the downregulation or loss of expression of certain ligands (Mistry and O'Callaghan, 2007) . Despite the importance of NKG2D in antitumour immunity, the mechanisms that control the expression of its ligands in malignant cells are poorly understood.
1-a,25-Dihydroxyvitamin D3 (1,25(OH)2D3), the active form of vitamin D, primarily regulates calcium homoeostasis in intestine, bone, kidneys, and parathyroid gland. It binds to the vitamin D receptor and regulates gene and miRNA expression to execute its antitumour effect. 1-a,25-Dihydroxyvitamin D3 shows antiproliferative and pro-differentiation effects in many malignant cells and reduces the development and growth of tumours in preclinical models (Trump et al, 2010) . In addition to these antiproliferative effects, 1,25(OH)2D3 modulates the expression of mediators of apoptosis such as Bax, Bcl-2, and Bcl-XL and directly induces apoptosis via caspase activation (Kizildag et al, 2012; Vuolo et al, 2012; Zhang et al, 2013) . More recently, 1,25(OH)2D3 was reported to enhance the susceptibility of melanoma cells to the cytotoxicity of NK cells (Lee et al, 2011) .
In this study, we extended the function of 1,25(OH)2D3 to the enhancement of NK susceptibility of other malignant cells, including the haematological tumour cell line Kasumi-1 and the solid tumour cell line MDA-MB-231, and explored the possible underlying mechanisms of the observed effects.
MATERIALS AND METHODS
Cell culture and treatment with 1,25(OH)2D3. Kasumi-1and K-562 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum. MDA-MB-231, MCF-7, and HEK-293T cells were cultured in DMEM supplemented with 10% fetal bovine serum. NK92 cells were maintained in RPMI 1640 supplemented with 10% human A þ serum and 20 ng ml À 1 IL-2. All cell lines were maintained at 37 1C in a humidified atmosphere of 5% CO 2 and used in the log phase of growth for all experiments. For 1,25(OH)2D3 treatment, cells were treated with 0.01, 0.05, 0.1, or 0.5 nM 1,25(OH)2D3 for 24 h. For the control group, 0.1% ethanol was added to culture medium.
Enrichment of primary polyclonal NK cells. CD3
À CD56 þ NK cells were enriched from human peripheral blood mononuclear cells (PBMC) of healthy donors, using the MACS technology (Miltenyi Biotec, Cologne, Germany) . PBMCs were first depleted of CD3 þ cells, and then positive selection of CD56 þ cells was carried out according to the manufacturer's protocol. Enrichment of CD3-CD56 þ NK cells was confirmed by flow cytometry, using the anti-human mAb anti-CD3-PE-Cy-7 and anti-CD56-APC (BD Bioscience, San Diego, CA, USA). Natural killer cells were cultured for 48 h in the presence of 250-500 IU ml À 1 IL-2 (Chiron Cooperation, Emeryville, CA, USA) before assaying.
Killing activity analysis of NK cells. CytoTox 96 NonRadioactive Cytotoxicity Assay was performed as described previously (Tsuboi et al, 2011) . Briefly, target cells were washed with PBS, resuspended with fresh NK92 culture medium, and seeded in a 96-well plate at a density of 5000 cells per well. NK92 cells or primary human NK cells were added at effector-to-target (E:T) ratios of 32 : 1, 16 : 1, and 8 : 1 and incubated for 4 h at 37 1C in a humidified atmosphere of 5% CO 2 . The supernatant was harvested and subjected to analysis by the CytoTox 96 NonRadioactive Cytotoxicity Assay. The killing effect of NK cells against target cells was assessed with the following equation: Cytotoxicity ¼ (Experimental À Effector spontaneous À Target spontaneous)/(Target maximum À Target spontaneous) Â 100%. 0 . Mutagenesis was performed using a QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), and all the adenines of miRNAbinding sequences were substituted with thymines. The empty vector (psi-CHECK2) was used as a negative control. Wild-type (wt) or mutant (mut) 3 0 -UTR vectors were cotransfected with miR302c and miR-520c mimics or negative controls into 293T cells using Lipofectamine 2000 (Invitrogen). The luciferase activity was measured 48 h later using the Dual-Luciferase Reporter Assay System (Promega). The Renilla luciferase values were normalised to firefly luciferase values, and the ratio of Renilla/firefly values is presented. The experiments were performed independently in triplicate.
RNA extraction, reverse transcription, and quantitative real-time PCR. Total RNA was extracted using TRIzol (Invitrogen) according to the manufacturer's instructions. cDNA was synthesised with the MLV transcriptase Kit (Invitrogen). miR-302c and miR-520c expression was assayed using a Bulge-LoopTM miRNA qRT-PCR primer (GenePharma, Shanghai, China) and Platinum SYBR Green qPCR SuperMix-UDG with ROX (Invitrogen) on a LightCycler 480 (Roche, Basel, Switzerland) according to the manufacturer's instructions. U6 small nuclear RNA, purchased from RiboBio (Guangzhou, China), was used as an internal control. The inhibitory effects on MICA, MICB, and ULBP2 mRNAs were evaluated using qRT-PCR, with GAPDH as an endogenous control. The sequences of the qRT-PCR primers were the following: for MICA:
The fold changes were calculated using relative quantification with the 2 À DDCt method. All of the reactions were performed in a 20-ml reaction volume in triplicate.
Western blot analysis. The cells were washed three times with PBS and then lysed in RIPA buffer in the presence of proteinase inhibitor cocktail (Shanghai Shenergy Biocolor BioScience and Technology Company, Shanghai, China). The protein concentration was determined using a BCA assay (Bios, Beijing, China). Aliquots (25 mg) were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with primary antibodies against ULBP2 and MICA/B (sc-80419, sc-23870, and sc-80527, respectively, mouse monoclonal; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at room temperature for 2 h, washed extensively with 0.1% Tween-20 in PBS, and incubated with secondary antibodies conjugated to horseradish peroxidase at 1 : 1000 dilutions. The intensity of the protein fragments was visualised using an X-ray image film processor (Kodak, Rochester, NY, USA). Measurement of the secretion of IFN-g by enzyme-linked immunosorbent assay. Cells treated with different concentrations of 1,25(OH)2D3 for 24 h were washed with PBS and resuspended with fresh NK92 culture medium and seeded into 96-well plates at a density of 5000 cells per well. NK92 cells were added at E:T ratios of 16 : 1 and incubated for 4 h at 37 1C in a humidified atmosphere of 5% CO 2 . The supernatant was harvested, and IFN-g was quantified using an enzyme-linked immunosorbent assay (ELISA) (Human IFN-g ELISA Kit II, Cat 550612; BD Pharmingen, San Diego, CA, USA) according to the manufacturer's instructions. The intensities of the cytokine signals were analysed using an ELISA reader (Bio-Rad; Hercules, CA, USA). 1-a,25-Dihydroxyvitamin D3 downregulates miR-302c and miR-520c. To explore the potential mechanisms by which 1,25(OH)2D3 enhances the susceptibility of Kasumi-1 and MDA-MB-231 cells to NK92 cells, we screened the miRNAs that were modulated by 1,25(OH)2D3 in Kasumi-1 cells using a miRNA microarray (Figure 2A ). Two highly downregulated miRNAs, miR-302c and miR-520c, provoked our interest because of their tumour-suppressing roles in cancer cells (Keklikoglou et al, 2012; Cai et al, 2013; Liang et al, 2013) . The effect of 1,25(OH)2D3 in downregulating miR-302c and miR-520c was confirmed using qRT-PCR. As shown in Figure 2 Figure S2) . Upregulation of miR-302c or miR-520c by their mimics remarkably reduced the viability of Kasumi-1 cells upon co-incubation with NK92 cells, whereas suppression of the activity of miR-302c or miR520c by their respective AMOs improved the resistance of Kasumi-1 cells to NK92 cells ( Figure 3B , Po0.01). Similar observations were made in MDA-MB-231 cells ( Figure 3C , Po0.01). We next evaluated the secretion of INF-g. As shown in Figure 3D , transfection of miR-302c or miR-520c mimics reduced the secretion of INF-g to o50% (Po0.01) compared with the negative control in both Kasumi-1 and MDA-MB-231 cells. By contrast, miR-302c or miR-520c ASO transfection dramatically increased INF-g secretion. Taken together, these observations indicate that miR-302c and miR-520c regulate 1,25(OH)2D3-mediated susceptibility of Kasumi-1 and MDA-MB-231 cells to NK cells.
Both miR-302c and miR-520c target the NKG2D ligands MICA, MICB, and ULBP2. To determine the mechanisms by which miR-302c and miR-520c regulate 1,25(OH)2D3-mediated susceptibility of Kasumi-1 and MDA-MB-231 cells to NK cells, we used the bioinformatic prediction algorithm TargetScan to analyse the direct mRNA targets of miR-302c and miR-520c. Both miR-302c and miR-520c have the same 'seed' sequence and have the same targets ( Figure 4A ). Of all the hypothetical targets of miR-302c and miR-520c, MICA, MICB, and ULBP2 were of the most interest because these are NKG2D ligands reported to be VitD hsa-miR-551b* hsa-miR-559 hsa-miR-889 hsa-miR-500a hsa-miR-17* hsa-miR-199b-5p
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hsa-miR-943 hsa-miR-150 hsa-miR-3178 hsa-miR-4279 hsa-miR-1246 hsa-miR-29a hsa-let-7b hsa-miRPlus-A1086 hsa-miRPlus-A1087 hsa-miR-199a-3p hsa-miRPlus-J1011 . To further identify whether MICA, MICB, and ULBP2 responded to miR-302c and miR-520c through direct 3 0 -UTR interactions, we cloned the wt 3 0 -UTRs of the putative miR-302c and miR-520c targets (MICA-wt, MICB-wt, and ULBP2-wt) and mutated Figure 4 . miR-302c and miR-520c suppress the expression of MICA, MICB, and ULBP2 by targeting their 3 0 -UTRs. (A) Sequences of the reporter constructs containing the predicted miR-302c-and miR-520c-binding sites in the 3 0 -UTRs of MICA, MICB, and ULBP2. (B) The overexpression of miR-302c or miR-520c miRNA mimic significantly attenuated the luciferase activities of the wt-MICA, wt-MICB, and wt-ULBP2 3 0 -UTRs in 293T cells. The cotransfection of WT or mut 3 0 -UTR and miRNA is indicated. (C-E) miR-302c and miR-520c mimics or AMO were transfected into Kamusi-1 cells for 48 h, and the mRNA levels of MICA, MICB, and ULBP2 were evaluated by qRT-PCR. (C) The protein levels of MICA, MICB, and ULBP2 were detected by western blot (D) and flow-cytometry analysis (E). (F-H) miR-302c and miR-520c mimics or AMO were transfected into MDA-MB-231 cells for 48 h, and the mRNA levels of MICA, MICB, and ULBP2 were evaluated by qRT-PCR (F). The protein levels of MICA, MICB, and ULBP2 were detected by western blot (G) and flow-cytometry analysis (H). The results are expressed as the means ± s.d.; n ¼ 3, *Po0.01 compared with the control.
sequences (MICA-mt1 þ 2, MICB-mt1 þ 2, and ULBP2-mut) individually into a reporter plasmid (pSi-CHECK2) downstream of the Renilla luciferase gene ( Figure 4A , Po0.01). These plasmids, together with miR-302c or miR-520c mimic, were transiently transfected into 293T cells. The transfection of pSi-CHECK2 together with miR-302c or miR-520c mimic was used as the negative control. A dual-luciferase reporter assay system was used to detect luciferase expression 48 h after transfection. The results demonstrated that miR-302c or miR-520c mimic attenuated the fluorescence of MICA-wt, MICB-wt, and ULBP2-wt by more than two-fold compared with the negative control ( Figure 4B ; Po0.01), whereas MICA-mt1 þ 2, MICB-mt1 þ 2, and ULBP2-mut exhibited abrogated responses to miR-302c and miR-520c ( Figure 4B , Po0.01). To further confirm the potential role of miR-302c or miR-520c in the regulation of MICA, MICB, and ULBP2, we evaluated their mRNA and protein expression levels in Kasumi-1 and MDA-MB-231 cells following the introduction of miR-302c and miR-520c mimics or AMOs. Transfection of miR-302c or miR-520c mimics led to notable decreases in MICA, MICB, and ULBP2 mRNA levels, whereas transfection of miR-302c or miR520c AMOs upregulated MICA, MICB, and ULBP2 mRNA level in Kisumi-1 cells ( Figure 4C , Po0.01) compared with the negative control. Consistently, the proteins of MICA, MICB, and ULBP2 in Kisumi-1 cells were downregulated by miR-302c and miR-520c mimics and upregulated by AMO transfection detected by both western blot ( Figure 4D ) and flow-cytometry analysis ( Figure 4E ). Similar observations were made in MDA-MB-231 cells ( Figure 4F -H). Collectively, these data demonstrate that miR-302c and miR520c are able to suppress the expression of MICA, MICB, and ULBP2 by targeting their 3 0 -UTRs.
MICA, MICB, and ULBP2 expression increases in response to 1,25(OH)2D3 treatment, an effect that is inversely correlated with miR-302c and miR-520c expression. Based on the results that miR-302c and miR-520c suppressed the expression of MICA, MICB, and ULBP2, we assessed the correlations between the three NKG2D ligands and miR-302c and miR-520c in cancer cells upon 1,25(OH)2D3 treatment. MICA, MICB, and ULBP2 mRNAs were upregulated in a 1,25(OH)2D3 dose-dependent manner in Kasumi-1 cells ( Figure 5A , Po0.01). Similar observations were made in MDA-MB-231 cells ( Figure 5B , Po0.01). By contrast, miR-302c and miR-520c decreased in a dose-dependent manner in Kasumi-1 cells ( Figure 5C , Po0.01) and MDA-MB-231 cells ( Figure 5D , Po0.01). Taken together, these results indicate that MICA, MICB, and ULBP2 expression levels were inversely correlated with miR-302c and miR-520c expression in Kasumi-1 and MDA-MB-231 cells exposed to 1,25 (OH)2D3. collected and subjected to the killing assay by NK92 cells. MICA, MICB, and ULBP2 overexpression in miRNAs ectopically expressed that MDA-MB-231 cells increase the secretion of IFN-g to 80% of the vector control ( Figure 6A ). Besides, the killing effect was also obviously improved in MDA-MB-231cells overexpressing MICA, MICB, or ULBP2 ( Figure 6B ). Taken together, these results indicate that MICA, MICB, or ULBP2 is functional contribution to the 1,25(OH)2D3-mediated susceptibility of malignant cells to NK cells via the miR-302c/miR-520c-NKG2D ligands pathway.
DISCUSSION
Vitamin D is a major cancer-chemopreventive agent. This anticancer potential is because of the role of 1,25(OH)2D3 as a transcription factor that regulates cell growth, differentiation, and apoptosis, which are central mechanisms in the progression of cancer (Deeb et al, 2007) . The studies presented here demonstrated that miR-302c and miR-520c were downregulated in response to 1,25(OH)2D3 treatment and contributed to the susceptibility of malignant cells to NK cells. Target analysis identified that both miR-302c and miR-520c targeted the NKG2D ligands MICA, MICB, and ULBP2 and suppressed their mRNA and protein levels.
Our data indicate that 1,25(OH)2D3 enhanced the killing effect of NK cells against malignant cells through a miR-302c/miR-520c/ NKG2D ligand pathway. NKG2D ligands are a group of MHC class I-like molecules that act as molecular danger signals to alert the immune system to infected or neoplastic cells. One common strategy that tumour cells employ to elude immune response is the downregulation or loss of expression of certain ligands. In animal models of spontaneous tumour formation, the absence of NKG2D results in enhanced formation of aggressive tumours (Guerra et al, 2008) . In other mouse models, transfection with NKG2D ligands results in NKG2D-mediated tumour rejection, whereas higher expression of NKG2D ligands results in an increased incidence of certain tumours (Cerwenka et al, 2001; Diefenbach et al, 2001; Wiemann et al, 2005; Guerra et al, 2008) . In the present study, we found evidence that miR-302c and miR-520c modulated the expression of the NKG2D ligands MICA, MICB, and ULBP2 by targeting their 3 0 -UTRs. The introduction of miR-302c or miR-520c mimics into Kasumi-1 and MDA-MB-231 cells reduced the mRNA and protein expression of those NKG2D ligands, whereas the introduction of miR-302c or miR-520c AMO increased their expression. Upon 1,25(OH)2D3 treatment, MICA, MICB, and ULBP2 expression was elevated and inversely correlated with miR-302c and miR-520c levels. Besides, upon 1,25(OH)2D3 treatment, miR-302c or miR-520c AMO notably increased the susceptibility of Kasumi-1 and MDA-MB-231 cells to NK cell cytotoxicity. More importantly, upon 1,25(OH)2D3 treatment, reintroduction of MICA, MICB, and ULBP2 reverses the miR-302c-and miR-520c-mediated resistance of malignant cells to the cytotoxicity of NK cells. We did not further examine whether MICA, MICB, and ULBP2 modulated 1,25(OH)2D3-mediated cytotoxicity, given that many studies have confirmed the roles of these proteins in this context. (Yadav et al, 2009; Trotta et al, 2012) . Cancer immunotherapy comprises a variety of treatment approaches; great interest has surrounded the activation of the immune system as an oncolytic agent owing to its ability to induce death in a range of human malignancies while sparing normal cells. In this paper, we propose that modulation of the miR-302c/miR-520c-NKG2D ligand pathway may be a valuable strategy to increase the susceptibility of both haematological and solid tumour cells to NK cells. 
